What's ahead for COVID-19 drugs and vaccines in 2021
Hello,
Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and this week in healthcare news:
If you're new to this newsletter, $4 Tips, comments? Email me at lramsey@insider.com or tweet $4. Let's get to it...
As you might expect, there'll be no newsletter Monday. Have a great long weekend, and see you Tuesday!
Following Pfizer's vaccine approval, there's still $4 as drugmakers look to get vaccines as well as COVID-19 treatments into more people.
Andrew Dunn rounded up 10 newsworthy moments to keep an eye out for in the remainder of 2021.
They include updates on new antiviral treatments as well as when we might get shots authorized for kids 12 and under.
>$4
Investors this summer picked out biotechs $4.
For those closely following the biotech industry, it may come as no surprise to find that a good number of the companies are based in one of two places: $4 or $4
Andrew and Allison DeAngelis have the bicoastal lists up this week.
>$4
The $1.4 billion One Medical-Iora deal closed on Wednesday.
Mohana Ravindranath spoke to the leaders of the two (now one) companies to $4
The thinking: One Medical wants to treat people when they're young, but also when they age into Medicare at 65.
"If we're going to try to attract you, how about your parents or your grandparents? Or if you have kids, your kids. We're speaking across a common brand, and ultimately across common technology platforms," One Medical CEO Amir Rubin told us.
More stories that kept us busy this week:
- Be sure to check out $4
- The jury's $4 for Theranos founder Elizabeth Holmes' trial. $4
- Psychedelics companies are acting like biotechs. So maybe it shouldn't be a big surprise that some top biotech VCs are $4. Yeji Jesse Lee has the story of $4, which has drawn backing from top healthcare investors.
- Lydia
